Center News

New squamous cell carcinoma drug target discovered

Vasioukhin and colleagues find alpha-catenin protein acts as a tumor suppressor, cell growth control mechanism revealed

May 30, 2011
Dr. Valeri Vasioukhin

Dr. Valeri Vasioukhin and colleagues found a protein called alpha-catenin acts as a tumor suppressor; they also have unlocked the mechanism by which this protein controls cell proliferation.

Center News file photo

Hutchinson Center researchers have discovered a new drug target for squamous cell carcinoma, the second most common form of skin cancer. Scientists in the Human Biology Division laboratory of Dr. Valeri Vasioukhin found a protein called alpha-catenin acts as a tumor suppressor and they also have unlocked the mechanism by which this protein controls cell proliferation.

The findings by Vasioukhin and lab colleagues Bridget Kreger, former staff member Marianna Rudakova, and Drs. Mark Silvis, Olga Klezovitch and Wen-Hui Len (now at Rockefeller University) appeared May 24 in Science Signaling.

For the study, the researchers studied mice bred to lack a copy of the gene that makes the protein alpha-catenin in hair follicle stem cells. The mice developed squamous cell carcinoma.

“The fact that alpha-catenin-deficient mice developed skin cancer led us to conclude that the loss of this protein is an important event in cancer development, and that alpha-catenin functions as a tumor suppressor,” Vasioukhin said. “We also found that unlike normal cells, alpha-catenin-mutant cells cannot stop dividing when they become very crowded in the Petri dish—this characteristic is one of the hallmarks of cancer cells.”

Yap1: A likely new target for treatment

The researchers also teased out the mechanisms by which the protein suppresses tumor growth. They found that alpha-catenin controls the activity of a protein called Yap1, which, if activated, can cause cancer.

“We found that alpha-catenin controls cell proliferation by regulating Yap1, which is active in cells missing alpha-catenin. Therefore, Yap1 is likely to be an excellent target for the treatment of patients with squamous cell carcinoma,” Vasioukhin said.

More than 700,000 new cases of squamous cell carcinoma are diagnosed each year. This form of skin cancer arises in the cells that make up most of the skin’s upper layers (epidermis). Squamous cell malignancies may arise in many areas of the body including the mucous membranes and genitals, but are most common in areas frequently exposed to the sun, such as the rim of the ear, lower lip, face, scalp, neck, hands, arms and legs.

The National Cancer Institute funded this research, which was also supported in part by a Chromosome and Metabolism and Cancer training grant from the National Institutes of Health. In addition to researchers in the Hutchinson Center’s Human Biology Division, co-authors included investigators from Dermatopathology Northwest in Bellevue, Wash.; Harvard University; and the University of Pennsylvania Medical School.

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.